This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards, JenaValve would control market, US FTC expert testifies

By Wesley Brown ( November 24, 2025, 23:19 GMT | Insight) -- Edwards Lifesciences and JenaValve, if their merger is permitted, would control the entire market for transcatheter aortic valve replacement devices used to treat aortic regurgitation, an expert witness testified for the US Federal Trade Commission on Monday. Nathan Wilson, formerly the FTC's Deputy Assistant Director in the Bureau of Economics, said there is a "high likelihood" that the proposed merger would harm competition and consumers.Edwards Lifesciences and JenaValve, if their merger is permitted, would control the entire market for transcatheter aortic valve replacement devices used to treat aortic regurgitation, an expert witness testified for the US Federal Trade Commission on Monday....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login